Eupraxia Pharmaceuticals Inc. Common Stock (EPRX)
Company finances score is on the low side; price trend score is above the middle.
EPRX scores higher than 69% of the 1,101 tickers we compare it with (Health Care).
As of 10 October 2026, Eupraxia Pharmaceuticals Inc. Common Stock (EPRX) scores 50 out of 100 on the Market Census six-factor composite, which puts it at the Average score level. The score is made from six named factors: price trend, strength vs the market, company finances, insider trades, market mood and recent momentum. It records what they read on 10 October 2026, and it is not investment advice.
Updated · scores usually change about once a day
Key statistics
Market fields as reported. An em-dash means we hold no value for this ticker — most of the universe has no daily price or volume read.
- Relative volume
- 1.24× 30-day average
- 52-week range
- 5.25 – 9.32
- Market cap
- $771.11M
- Earnings date
- —
- Volume
- 1,052,001
- Avg. volume (30d)
- 848,562
- Open
- 7.57
- Previous close
- 7.57
- Day's range (regular session)
- 7.28 – 7.70
The last trade can be an extended-hours trade, so it can sit outside the regular-session range.
Shown without a peer ranking — we hold no percentile for these yet, so there is nothing here to locate them against.
- Beta
- 1.14
- P/E (TTM)
- —
- EPS (TTM)
- -0.94
Score breakdown · six named factors
Each bar is one part of the score, from 0 to 100. Read what the score means.
What the score says about EPRX right now
Eupraxia Pharmaceuticals Inc. Common Stock (EPRX) currently scores 50/100 on the Market Census six-factor composite, at the Average score level. EPRX is -1.45% on the day and +3.04% over five sessions as of the most recent tick. Average sits in the middle. The good and the bad in EPRX's data roughly balance out right now. EPRX's strongest factor is price trend at 79/100 — a strong read on which way the price has been going. The weakest factor is company finances at 0/100 — well below average company numbers. A low company-finances reading is the canonical "value trap" warning: technical setups on broken fundamentals don't tend to compound.
Generated from the six-factor breakdown above. Changes when the underlying scores do, usually about once a day. More on what the score means.
See EPRX in the scanner
This page is free to read with no account at all. Signing up takes an email and a password: a free account runs the scanner on the top 10 scored rows of any scan, keeps one saved screen, a 5-ticker watchlist, and opens 12 ticker detail pages a day. The card is what starts a 30-day Premium trial — $0 that day, then $19.99/month from day 30, cancel online any time before then — and that is what turns on every matching row instead of the first 10, alerts, the 200-ticker watchlist and recent insider buys (SEC Form 4).
Recent EPRX news
Latest headlines that name Eupraxia Pharmaceuticals, one per story, sourced from Market Census’s news feed (Polygon/Massive + Finnhub).
- Eupraxia Pharmaceuticals to Present at Upcoming American College of Gastroenterology (ACG) and United European Gastroenterology (UEG) Medical ConferencesGlobeNewswire Inc.
- Eupraxia Says Resolve Trial Updated Data Suggest Annual Dosing Possible in EoE PatientsYahoo
- Eupraxia Pharmaceuticals Reports 52-Week Data from the Highest Dose Cohort of EP-104GI in its Ongoing Phase 1b/2a RESOLVE Trial for the Treatment of Eosinophilic EsophagitisGlobeNewswire Inc.
- Eupraxia Pharma (EPRX): When Painful Swallowing Nearly Disappeared, Investors Took NoticeYahoo
- Eupraxia Pharmaceuticals Completes Transfer to the Nasdaq Global Select Market and Announces Participation in Upcoming Investor ConferencesYahoo
We hide 2 more that told readers to buy or sell, or gave a price target.
Saved snapshot; the news and prices on this page can be an hour old or more.
Similar setups in Health Care right now
Six health care tickers whose composite scores are closest to EPRX’s 50, all within 1 point.
Sorted by closeness to EPRX’s composite score within Health Care. Saved snapshot; can be an hour old or more. Run the full scanner →
Prices delayed about 15 minutes; scores usually change about once a day. Not investment advice — see risk disclosure.